We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Spectrum Pharmaceuticals Inc | NASDAQ:SPPI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.03 | 1.14 | 0.9785 | 0 | 01:00:00 |
From May 2019 to May 2024
Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (Nasdaq: SPPI) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
The investigation focuses on a statement by Spectrum that it failed to disclose that the Food & Drug Administration advised it not to submit a New Drug Application for its drug candidate apaziquone back in December of 2012.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006052/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile: 888-713-1125brian@lundinlawpc.comhttp://lundinlawpc.com/
1 Year Spectrum Pharmaceuticals Chart |
1 Month Spectrum Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
